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Bronchoalveolar Lavage
Fluid Galactomannan
for Diagnosis of Invasive
Pulmonary Aspergillosis
To the Editor—We read the article by
Maertens et al [1] with great interest. In
a series of 58 patients who received a di-
agnosis of proven or probable invasive as-
pergillosis (IA), the authors confirmed
previous work that the diagnostic perfor-
mance of galactomannan antigen levels in
bronchoalveolar lavage (BAL) fluid sam-
ples is good and that the procedure is safe
in critically ill hematology patients.
However, the article leaves both the
readers of Clinical Infectious Diseases and
the treating physicians of patients who
have a high risk of IA with the burning
question whether performance of BAL has
additional diagnostic yield in comparison
with serum galactomannan testing. The
most convincing argument to persuade
hematologists and pulmonologists to per-
form BAL would be that determination of
galactomannan levels in BAL fluid samples
has a higher sensitivity without a loss of
specificity. In addition, for patients with a
positive serum galactomannan level, at-
tempts to make a culture-positive diag-
nosis can be done by performing BAL,
which is increasingly important in the
context of recent data on emerging azole
resistance in Aspergillus fumigatus [2]. Fur-
thermore, patients might be diagnosed
with a mixed (bacterial and/or fungal) in-
fection.
To our surprise, the authors did not
provide any data on the sensitivity of ga-
lactomannan in BAL in comparison with
in serum samples. As an explanation, they
state that such a comparison is not pos-
sible, because a positive serum galacto-
mannan test result was part of the gold
standard for the diagnosis of IA. Although
this argument is true for probable cases of
IA, incorporation of a positive serum ga-
lactomannan test result as a criterion for
case classification is unnecessary for prov-
en cases.
Therefore, we hope that Maertens et al
[1] can provide us the data on the sen-
sitivity of BAL galactomannan measure-
ments for the substantial subset of patients
with proven pulmonary IA (31 of 58 pa-
tients). We are particularly interested in
the data for patients with proven pul-
monary IA and not other molds, because
other molds will not be detected by means
of galactomannan testing. Therefore, even
if galactomannan levels in BAL samples
would yield 100% sensitivity, a negative
BAL sample test result should always be
followed by tissue diagnostics to exclude
other invasive fungal infections. In addi-
tion, data on mixed infections, which were
diagnosed after BAL performance but
were unrecognized before, would also be
valuable, to serve as another argument in
favor of BAL performance.
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Galactomannan Detection
and Diagnosis of Invasive
Aspergillosis
To the Editor—The article on bron-
choalveolar lavage (BAL) galactomannan
enzyme immunoassay (EIA) for diagnosis
of invasive aspergillosis of patients with
hematologic diseases raises some impor-
tant points [1]. The authors, like others
before them, seem not to have fully ap-
preciated the fact that, with such a high
prior probability of disease—35% in their
series—the galactomannan EIA is being
used to confirm the diagnosis. Thus, the
posterior probability for a positive test re-
sult (ie, the positive predictive value
[PPV]) should be the highest possible.
Their data show that the highest PPV was
80.4% and was associated with a threshold
optical density (OD) index of 1.5–2. One
cannot confirm and exclude a diagnosis
using the same threshold without paying
a price in terms of false-positive and false-
negative results, respectively. This is shown
clearly in this article and also in a recent
meta-analysis of serum and plasma galac-
tomannan [2]. These effects are displayed
in Table 1 for 2 hypothetical populations
of 100 patients: one with a prior proba-
bility (prevalence) of IA of 8% for whom
serum and plasma specimens are tested
once or twice weekly for galactomannan,
and the other with a prevalence of 35%
in which a BAL fluid specimen was tested
for the same antigen. It is clear that one
needs to choose a low threshold in both
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Table 1. Hypothetical Populations of 100 Patients
OD index threshold
Plasma/serum prevalence of IA, 8% BAL prevalence of IA, 35%
Cases of IA, 8 Cases of no IA, 92 Cases of IA, 35 Cases of no IA, 65
False-negative results False-positive results False-negative results False-positive results
0.5 2 17 0 12
1 2 8 2 7
1.5 3 5 3 6
NOTE. BAL, bronchoalveolar lavage; IA, invasive aspergillosis; OD, optical density.
scenarios to obtain the lowest rate of false-
negative results and that the converse is
true to obtain a low number of false-pos-
itive results. The numbers differ but the
principle remains the same. The question
is: what do we want from a test? Staring
at the bare facts does not help us here to
address the issue. BAL fluid samples are
not suitable in a screening test for obvious
reasons and should only be used to de-
termine an etiology. Then, we need con-
fidence in knowing that the test has a high
PPV. On the other hand, the galactoman-
nan test is most often used for screening,
and here we want the lowest number of
false-negative results, because we want to
exclude the diagnosis of IA. Consequently,
an optical density index of 0.5 is the most
appropriate. It may be that using the
higher threshold to confirm a case of IA
on the basis of plasma or serum test result
is appropriate, but that requires further
study.
In any event, we clearly have at least 2
ways in which to employ galactomannan:
first, screening when the prevalence is low
(eg, !10%) to exclude IA when the test
result is negative (optical density index,
0.5); second, testing BAL fluid, in which
case a positive test result (optical density
index,1.0) supports the diagnosis of IA.
One could reason that blood or serum
samples that yield an optical density index
11.5 could also support a diagnosis of IA,
especially if the prevalence is relatively
high (eg, 110%). This will mean several
thresholds for different purposes, different
samples, and perhaps different patient
populations, which will help us use the
test optimally, allowing it to come of age.
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Reply to Rijnders and Slobbe
and to Donnelly and Leeflang
To the Editor—We appreciate the com-
ments by Rijnders and Slobbe [1]. Regular
testing for the detection of serum or
plasma galactomannan (GM) has become
increasingly popular for the early diag-
nosis of invasive aspergillosis (IA), espe-
cially in patients with prolonged profound
neutropenia and in allogeneic stem cell
transplant recipients. However, the excel-
lent performance characteristics of serum
GM testing that are usually seen in these
particular patient groups cannot be dem-
onstrated in nonneutropenic hematology
patients [2] and in nonhematology pa-
tients, including intensive care unit pa-
tients [3]. This limitation calls for other
microbiological tests, including analysis of
bronchoalveolar lavage (BAL) fluid, to es-
tablish the diagnosis of IA. As stated by
Rijnders and Slobbe, the question remains
whether GM testing on BAL fluid results
in any additional diagnostic yield in com-
parison with serum GM testing. In our
study [4], paired BAL fluid and serum GM
test results (taken on the same day and
before antifungal treatment was given)
were available from 10 neutropenic and
19 nonneutropenic patients with proven
IA (Table 1). Using a cutoff index of 1.0,
the sensitivity of GM detection in BAL
fluid was 100% in neutropenic patients
and 94.7% in nonneutropenic patients (P
1 .99); however, using a cutoff index of
0.5, the sensitivity of serum GM testing
was significantly better in neutropenic ver-
sus nonneutropenic patients (90% vs
36.8%; Pp .008). Overall, determination
of GM levels in BAL fluid seems to have
a higher sensitivity than serum testing.
Although we tend to disagree with the
general statement that azole resistance in
Aspergillus fumigatus is emerging [5] and
that a negative BAL sample result should
always be followed by tissue diagnostics,
we certainly appreciate the added value of
BAL fluid examination. BAL fluid was cul-
ture positive for Aspergillus species in 18
of 29 cases, allowing species identification
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